Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival

Abstract

MRD-negative remission in CLL is achievable with alemtuzumab, leading to an improved overall and treatment-free survival.